The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Scientific presentation selector
Geo Regions
Important Notice Regarding the Scientific Information You Have Requested
You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.
Please acknowledge that you understand this before proceeding.
BackImportant Notice: The information provided here relates to investigational therapies. The safety and efficacy of these investigational therapies has not been proven.
Poster
Symbiotic-GI-03: a randomized, double-blind, phase 3 study of first-line PF-08634404, a PD-1/VEGF bispecific antibody, in combination with mFOLFOX6 in patients with metastatic colorectal cancer (mCRC)
Cathy Eng, Elena Élez, Julien Taieb, Rui-Hua Xu, Hiroya Taniguchi, Tanios S. Bekaii-Saab, Jeanne Tie, Myriam Chalabi, Zhiyu Chen, Aman Opneja, Mark D. Kochenderfer, Yong Sang Hong, Donald A. Richards, Barbara Radecka, Yiyi Chen, Jill Clancy, Svitlana Tonkovyd, Xiaosong Zhang, Kimmie Ng
PD-1 x VEGF Bispecific Antibody | May 30, 2026 | ASCO 2026
C6461003 | NCT07222800
Poster
A phase 3 trial of a PD-1/VEGF bispecific antibody (PF-08634404) vs pembrolizumab in combination with platinum-based chemotherapy in first-line for locally advanced or metastatic non-small cell lung cancer (Symbiotic-Lung-01)
David Planchard, Martin Reck, Rachel Roberts-Thomson, Vishal Navani, Caicun Zhou, Filippo de Marinis, Akito Hata, Yasushi Goto, Noelia Vilarino, Enriqueta Felip Luis Paz-Ares, Yang Chih-Hsin, Jhanelle E. Gray, Smitha Menon, Matthew Mirsky, Kevin Kim, Matteo Setti, Melissa Johnson
PD-1 x VEGF Bispecific Antibody | March 25, 2026 | ESMO ELCC 2026
C6461001 | NCT07222566